In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 ...
Hosted on MSN14d
CHMP recommends AbbVie’s Rinvoq be approved for adult GCAThe European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with ... to receive a 7.5 mg or 15 ...
In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg ...
The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1The primary ...
1 In the first study period, patients were randomized to receive upadacitinib 7.5 mg or 15 mg in combination ... today and in the future." RINVOQ is approved in the European Union (EU) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback